The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index; 16 of the 28 sources its claims cite were checked for support.
Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial
Open accessAbstract
Background The DiRECT trial assessed remission of type 2 diabetes during a primary care-led weight-management programme. At 1 year, 68 (46%) of 149 intervention participants were in remission and 36 (24%) had achieved at least 15 kg weight loss. The aim of this 2-year analysis is to assess the durability of the intervention effect. Methods DiRECT is an open-label, cluster-randomised, controlled trial done at primary care practices in the UK. Practices were randomly assigned (1:1) via a computer-generated list to provide an integrated structured weight-management programme (intervention) or best-practice care in accordance with guidelines (control), with stratification for study site (Tyneside or Scotland) and practice list size (>5700 or ≤5700 people). Allocation was concealed from the study statisticians; participants, carers, and study research assistants were aware of allocation. We recruited individuals aged 20-65 years, with less than 6 years' duration of type 2 diabetes, BMI 27-45 kg/m 2, and not receiving insulin between July 25, 2014, and Aug 5, 2016. The intervention consisted of withdrawal of antidiabetes and antihypertensive drugs, total diet replacement (825-853 kcal per day formula diet for 12-20 weeks), stepped food reintroduction (2-8 weeks), and then structured support for weight-loss maintenance. The coprimary outcomes, analysed hierarchically in the intention-to-treat population at 24 months, were weight loss of at least 15 kg, and remission of diabetes, defined as HbA 1c less than 6·5% (48 mmol/mol) after withdrawal of antidiabetes drugs at baseline (remission was determined independently at 12 and 24 months). The trial is registered with the ISRCTN registry, number 03267836, and follow-up is ongoing. Findings The intention-to-treat population consisted of 149 participants per group. At 24 months, 17 (11%) intervention participants and three (2%) control participants had weight loss of at least 15 kg (adjusted odds ratio [aOR] 7·49, 95% CI 2·05 to 27·32; p=0·0023) and 53 (36%) intervention participants and five (3%) control participants had remission of diabetes (aOR 25·82, 8·25 to 80·84; p<0·0001). The adjusted mean difference between the control and intervention groups in change in bodyweight was -5·4 kg (95% CI -6·9 to -4·0; p<0·0001) and in HbA 1c was -4·8 mmol/mol (-8·3 to -1·4 [-0·44% (-0·76 to -0·13)]; p=0·0063), despite only 51 (40%) of 129 patients in the intervention group using anti-diabetes medication compared with 120 (84%) of 143 in the control group. In a post-hoc analysis of the whole study population, of those participants who maintained at least 10 kg weight loss (45 of 272 with data), 29 (64%) achieved remission; 36 (24%) of 149 participants in the intervention group maintained at least 10 kg weight loss. Serious adverse events were similar to those reported at 12 months, but were fewer in the intervention group than in the control group in the second year of the study (nine vs 22). Interpretation The DiRECT programme sustained remissions at 24 months for more than a third of people with type 2 diabetes. Sustained remission was linked to the extent of sustained weight loss. Funding Diabetes UK.
Overview
CoChat Summary
TL;DR
In the 2-year DiRECT trial, a primary care-delivered structured weight-management programme sustained type 2 diabetes remission in 35.6% of intervention participants versus 3.4% of controls. Remission was strongly related to maintained weight loss, occurring in 64% of those maintaining ≥10 kg loss and 70% of those losing ≥15 kg.
Key findings
- At 24 months, diabetes remission occurred in 53/149 (35.6%) intervention participants versus 5/149 (3.4%) controls (adjusted odds ratio 25.8, 95% CI 8.3–80.8; p<0.0001).
- Weight loss ≥15 kg occurred in 17/149 (11.4%) intervention participants versus 3/149 (2.0%) controls (adjusted odds ratio 7.49, 95% CI 2.05–27.32; p=0.0023); 24.2% (36/149) of the intervention group maintained ≥10 kg weight loss.
- Among all participants with weight data, remission at 24 months occurred in 29/45 (64.4%) who maintained ≥10 kg loss and 14/20 (70.0%) who lost ≥15 kg, versus 8/154 (5.2%) who failed to achieve 5 kg loss.
- Adjusted mean differences at 24 months favoured intervention for weight (−5.43 kg, 95% CI −6.87 to −3.99), HbA1c (−4.82 mmol/mol, 95% CI −8.28 to −1.36), systolic blood pressure (−3.43 mmHg, 95% CI −6.70 to −0.16), and quality-of-life VAS (4.64, 95% CI 0.39–8.89); serious adverse events in the second year were 9 in intervention versus 22 in control.
Methods
- Open-label, cluster-randomised controlled trial in UK primary care: 49 practices (23 intervention, 26 control), 306 recruited, intention-to-treat population 149 per group; participants were aged 20–65 years, had type 2 diabetes for <6 years, BMI 27–45 kg/m², and were not receiving insulin.
- Intervention (Counterweight-Plus) comprised total diet replacement (825–853 kcal/day formula diet) for 12–20 weeks, stepped food reintroduction, and structured weight-loss maintenance support; anti-diabetes and antihypertensive drugs were withdrawn at start, with protocols for reintroduction. Controls received best-practice care by guidelines.
- Co-primary outcomes at 24 months were weight loss ≥15 kg and remission (HbA1c <6.5%/<48 mmol/mol with no anti-diabetes medications); analyses were intention-to-treat using mixed-effects regression with practice as a random effect, and missing primary outcome data were assumed not met.
Limitations
- The paper states the trial was open-label, so participants and clinicians knew allocation; media coverage after the 12-month results may have attenuated between-group differences, and control-group personal weight loss and increased SGLT2 inhibitor use may have contributed to control-group changes.
- The paper states findings apply to type 2 diabetes diagnosed within the previous 6 years and may not extrapolate to other racial/ethnic groups such as South Asians; medication withdrawal is not standard guidelines, so some control participants might have sustained HbA1c below the remission cutoff if antidiabetic agents had been withdrawn.
- The paper states it was not powered for hard clinical outcomes and that exercise and sleep data were not yet analysed; evident from the text, 14.1% (42/298) did not attend the 24-month assessment, and 26 participants with no 24-month data were assumed not to have met either primary outcome.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
7 Valid · 5 Not valid · 7 Not checked · 68 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Several studies have now shown that weight loss of at least 10-15 kg frequently normalises blood glucose in people with short-duration type 2 diabetes, and DiRECT did this in a real-life primary care setting. 9-12”
What the sources say
- Not checked — no full text of the sourcecites [9] Sjostrom, 2014, Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications, JAMA source
- Partly supportedcites [10] Sjostrom, 2013, Review of the key results from the Swedish Obese Subjects (SOS) trial—a prospective controlled intervention study of bariatric surgery, J Intern Med sourceExperimental — accuracy not yet measured
The ‘Effects of bariatric surgery on remission of diabetes’ section reports frequent remission in patients with type 2 diabetes after surgery, including 72% of SOS patients at two years. It does not establish that losing at least 10–15 kg frequently normalises blood glucose specifically in people with short-duration diabetes. The separate claim about DiRECT is not attributed to this 2013 source. (LLM, conf=0.84)
- Partly supportedcites [11] Schauer, 2003, Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus, Ann Surg sourceExperimental — accuracy not yet measured
The Abstract reports that diabetes resolved in 83% of patients after gastric bypass, with a higher resolution rate among those with diabetes for less than five years. But the reported mean weight loss was 97 lb (about 44 kg); the paper does not establish that losing 10–15 kg is sufficient to frequently normalise blood glucose. (LLM, conf=0.86)
- Supportedcites [12] Lean, 2018, Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial, Lancet source
The Introduction (page not provided) states that other studies found weight loss of at least 10–15 kg could normalise blood glucose in people with short-duration type 2 diabetes. The Discussion also reports that DiRECT achieved remission in a routine primary-care setting, including 73% of participants who lost at least 10 kg. (LLM, conf=0.94)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“The 12-month intervention cost is under half of the average annual UK healthcare cost of a person with type 2 diabetes. 23”
What the sources say
- Could not verifycites [23] McCombie, 2018, Filling the intervention gap: service evaluation of an intensive nonsurgical weight management programme for severe and complex obesity, J Hum Nutr Diet sourceExperimental — accuracy not yet measured
The Discussion (p. 11) mentions potential savings on diabetes medications, and the Results (p. 9) report 12-month weight outcomes. Neither gives a 12-month intervention cost or an average annual UK healthcare cost for a person with type 2 diabetes; searches for those costs and the claimed comparison found no supporting passage. (LLM, conf=0.74)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Baseline characteristics were similar between groups. 15”
What the sources say
- Could not verifycites [15] Taylor, 2018, Clinical and metabolic features of the randomised controlled Diabetes Remission Clinical Trial (DiRECT) cohort, Diabetologia sourceExperimental — accuracy not yet measured
The Statistical analyses section says treatment-arm codes had not been broken and baseline data for the arms would be analysed later. The Baseline characteristics tables compare study areas, not intervention and control groups; the Participant recruitment section reports similar response rates, not similar baseline characteristics. Our copy therefore does not establish the claimed comparison. (LLM, conf=0.78)
plainn = 149- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“the twin cycle mechanism, driven by a damaging but reversible accumulation of ectopic fat within the liver and pancreas in susceptible individuals, has now been consistently observed. 6-8”
What the sources say
- Partly supportedcites [6] Lim, 2011, Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol, Diabetologia sourceExperimental — accuracy not yet measured
The Discussion reports that dietary energy restriction reversed the twin defects of beta-cell failure and insulin resistance alongside decreases in liver and pancreatic fat, and it discusses individual susceptibility. But it describes excess lipid accumulation as a hypothesis consistent with the data, rather than establishing it as the damaging driver; this study alone also does not establish that the mechanism has been consistently observed. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [7] Steven, 2016, Very low-calorie diet and 6 months of weight stability in type 2 diabetes: pathophysiological changes in responders and nonresponders, Diabetes Care source
- Not checked — no full text of the sourcecites [8] Henry, 1985, Glycaemic effects of intensive caloric restriction and isocaloric refeeding in non-insulin dependent diabetes mellitus, J Clin Endocrinol Metab source
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Total serious adverse events reported for the first 24 months of DiRECT were 15 in the intervention and 25 in the control group, in 11 and 19 participants respectively.”
plainn = 19- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
40 more claims
Create a free account to see all 87 claims and every source verdict.
- It may state two separate claims as one. 29
- Probably not a substantial claim. 16
- The quote only partly states this claim. 4
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Another meta-analysis of 11 RCTs with 6754 participants employing lifestyle intervention (calorie restriction, regular physical activity/exercise and frequent contact support from health care professionals) duration of at least 1 year, showed significantly better effects on A1C, lipids, and BP in those with >5% weight loss compared to those with <5% weight loss.688”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [688]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“It was similar (83% at 2 years) after non‐surgical weight loss >10 kg in DiRECT.”
From Clinical utility of liver function tests for resolution of metabolic dysfunction-associated steatotic liver disease after weight loss in the Diabetes Remission Clinical Trial (2025) · cites this paper as [7]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The most important feature for diet modification is a reduced-calorie meal plan, which is essential for effective weight loss.687–690”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [688]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Of 36 in the intervention group who maintained over 10 kg weight loss at 2 years, 29 (81%) were in remission.”
From 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study (2024) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“with 36% of participants in remission of type 2 diabetes.”
From 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study (2024) · cites this paper as [3]
Experimental — accuracy not yet measured
22 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Results · p. 10
“A total of 116/149 (77·9%) participants in the intervention and 140/149 (94·0%) in the control group attended the 24 month study assessment, thus overall 42/298 (14·1%) randomised participants did not attend at 24 months.”
§ Legends to Figures · p. 30
“| Number | 298 | 41 | 257 | p<0.0001 W |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ ABSTRACT · p. 5
“stepped food reintroduction (2-8 weeks)”
§ Study design and participants · p. 7
“stepped food reintroduction (6-8 weeks)”
Citations
Cites
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Lean, M. E., Leslie, W. S., Barnes, A. C., Brosnahan, N., Thom, G., McCombie, L., Peters, C., Zhyzhneuskaya, S., Al-Mrabeh, A., Hollingsworth, K. G., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33102-1 · Cited by 2,095
Self-citationSjöström, L. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12012 · Cited by 1,835
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetologia · doi:10.1007/s00125-018-4729-5 · Cited by 1,455
Chambers, E. S., Viardot, A., Psichas, A., Morrison, D. J., Murphy, K. G., Zac-Varghese, S. E. K., MacDougall, K., Preston, T., Tedford, C., Finlayson, G. S., et al. (2015) · Gut · doi:10.1136/gutjnl-2014-307913 · Cited by 1,424
Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus
Schauer, P. R., Burguera, B., Ikramuddin, S., Cottam, D., Gourash, W., Hamad, G., Eid, G. M., Mattar, S., Ramanathan, R., Barinas-Mitchel, E., et al. (2003) · Annals of Surgery · doi:10.1097/01.sla.0000089851.41115.1b · Cited by 1,183
Lim, E. L., Hollingsworth, K. G., Aribisala, B. S., Chen, M. J., Mathers, J. C., & Taylor, R. (2011) · Diabetologia · doi:10.1007/s00125-011-2204-7 · Cited by 1,164
Self-citationSjöström, L., Peltonen, M., Jacobson, P., Ahlin, S., Andersson-Assarsson, J., Anveden, Å., Bouchard, C., Carlsson, B., Karason, K., Lönroth, H., et al. (2014) · JAMA · doi:10.1001/jama.2014.5988 · Cited by 1,054 · cited 1×
“The conclusions reported here apply to people with type 2 diabetes diagnosed within the previous 6 years, and existing evidence has shown that remission, though still possible, is less likely after longer durations of disease.(8,10) As”
Backgroundle Roux, C. W., Astrup, A., Fujioka, K., Greenway, F., Lau, D. C. W., Van Gaal, L., Ortiz, R. V., Wilding, J. P. H., Skjøth, T. V., Manning, L. S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30069-7 · Cited by 850
Self-citationEight-year weight losses with an intensive lifestyle intervention: The look AHEAD study
The Look AHEAD Research Group (2014) · Obesity · doi:10.1002/oby.20662 · Cited by 842
Cited by
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Benetos, A., Biffi, A., Boavida, J.-M., Capodanno, D., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab484 · Cited by 6,485
Self-citation2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s002 · Cited by 4,792
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Self-citation2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s002 · Cited by 3,116
2. Classification and Diagnosis of Diabetes:Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Gaglia, J. L., Hilliard, M. E., Isaacs, D., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s002 · Cited by 2,433
Metadata
- Authors
- Lean, M. E. J., Leslie, W. S., Barnes, A. C., Brosnahan, N., Thom, G., McCombie, L., Peters, C., Zhyzhneuskaya, S., Al-Mrabeh, A., Hollingsworth, K. G., Rodrigues, A. M., Rehackova, L., Adamson, A. J., Sniehotta, F. F., Mathers, J. C., Ross, H. M., McIlvenna, Y., Welsh, P., Kean, S., Ford, I., McConnachie, A., Messow, C.-M., Sattar, N., & Taylor, R.
- Affiliations
- University of Glasgow (GB)
- Newcastle University (GB)
- Corresponding author
- Taylor, Roy
- ORCID
- Lean, Michael E J
- Leslie, Wilma S
- Barnes, Alison C
- Brosnahan, Naomi
- Thom, George
- McCombie, Louise
- Zhyzhneuskaya, Sviatlana
- Al-Mrabeh, Ahmad
- Hollingsworth, Kieren G
- Rodrigues, Angela M
- Rehackova, Lucia
- Adamson, Ashley J
- Sniehotta, Falko F
- Mathers, John C
- Welsh, Paul
- Kean, Sharon
- Ford, Ian
- McConnachie, Alex
- Messow, Claudia-Martina
- Sattar, Naveed
- Taylor, Roy
- Venue
- The Lancet Diabetes & Endocrinology
- Publisher
- Elsevier BV
- Published
- 2019-05
- Volume
- 7
- Issue
- 5
- Pages
- 344-355
- ISSN
- 2213-8587 (ISSN-L)
- OpenAlex
- W2919203803
- Cited by
- 1,017
- References
- 32
- Citations by year
- 2026: 107 · 2025: 144 · 2024: 179 · 2023: 154 · 2022: 154 · 2021: 131 · 2020: 98 · 2019: 47
- FWCI
- 56.66
- Type
- journal article
- Language
- en
- Open access
- green
- eprints.gla.ac.uk
- Licence
- cc-by-sa
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- The Lancet Diabetes & Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Northumbria Research Link (Northumbria University) (acceptedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- Newcastle University ePrints (Newcastle Univesity) (cc-by-nc-nd)
- Funders
- Diabetes UK as a strategic research initiative (13/0004691)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- type 2 diabetes remission, weight management, primary care intervention, total diet replacement, drug withdrawal, weight loss maintenance, HbA1c, weight loss, DIRECT trial, antihypertensive drugs, intention-to-treat analysis
- MeSH terms
- Adult, Aged, Continuity of Patient Care, Diabetes Mellitus, Type 2, Female, Follow-Up Studies, United Kingdom, Humans, Male, Middle Aged, Primary Health Care, Remission Induction, Time Factors, Cluster Analysis, Young Adult, Weight Reduction Programs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. https://app.cochat.ai/papers/10.1016/s2213-8587(19)30068-3
- The paper
- Lean, M. E. J., Leslie, W. S., Barnes, A. C., Brosnahan, N., Thom, G., McCombie, L., Peters, C., Zhyzhneuskaya, S., Al-Mrabeh, A., Hollingsworth, K. G., Rodrigues, A. M., Rehackova, L., Adamson, A. J., Sniehotta, F. F., Mathers, J. C., Ross, H. M., McIlvenna, Y., Welsh, P., Kean, S., . . . Taylor, R. (2019). Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(19)30068-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.